Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tarlatamab Alone or With Chemotherapy in Advanced Neuroendocrine Carcinomas
NCT07061080Phase 2Active, not recruiting
- Sponsor
- Spanish Group of Neuroendocrine Tumors
- Start
- Dec 2025
- Primary completion
- Dec 2028
- Modality
- Bispecific Antibodies, T-cell Engagers
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of tarlatamab in neuroendocrine carcinoma (NEC) (2 arms), sponsored by Spanish Group of Neuroendocrine Tumors. Primary endpoints: Progression-free Survival rate at 3 years and Overall Survival rate at 12 months. Started Dec 2025; status: active, not recruiting.
02
Drugs
tarlatamab
03
Conditions
neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on NCT07061080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07061080.